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Patients who lack a functioning spleen become vulnerable to sepsis caused by bacteria and, occasionally,
protozoa. The risk is higher in children and in those who have had immunosuppressive treatment, and
the risk remains lifelong. Overwhelming post-splenectomy infection (OPSI) occurs at an estimated incidence
of 0.23–0.42% per year, with a lifetime risk of 5%. Episodes of OPSI are emergencies, requiring
immediate parental antibiotics and intensive care; intravenous immunoglobulins may be useful. OPSI carries a
mortality of 38–69%. Streptococcus pneumoniae is the commonest infecting organism, accounting for 50–90%
of isolates from blood cultures in reported series; it is particularly common in children with sickle cell
disease. Less commonly, the infecting organisms are other bacteria, Babesia or Ehrlichia. OPSI may be, to some
extent, preventable by several interventions. These are surgical conservation of the spleen; immunization
against S. pneumoniae, Haemophilus influenzae type b, and Neisseria meningitidis; prophylactic antibiotics;
stand-by antibiotics; patient information sheets; and a medical alert bracelet. Asplenic patients living in
malaria-endemic areas require optimal prophylaxis. The initial step in prevention of OPSI is the creation of an
asplenia register, as many patients are not covered by these simple measures.
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INTRODUCTION
Surgical removal of the spleen results in: reduced clearance of
particulate antigens, be they extracellular (e.g. bacteria) or
intracellular (e.g. malaria); diminished response to new anti-
gens, particularly polysaccharides; impaired phagocytosis of
unopsonized and opsonized bacteria and cells; and decreased
levels of tuftsin and properdin [1]. Asplenic individuals are thus
particularly vulnerable to sepsis caused by bacteria and, occa-
sionally, protozoa. Such infections are often fulminant, with
high mortality. Similar risks of infection exist where the spleen
is non-functional, e.g. due to atrophy in sickle cell disease [2].
The commonest infecting organism in most series is Strepto-
coccus pneumoniae, which accounts for 50–90% of isolates from
blood cultures in many cohorts of patients [1,3]. It is particularly
common in children with sickle cell disease [2]. Haemophilus
influenzae type b was the second most frequent organism in the
era before the Hib conjugate vaccine. Other bacteria include
Streptococcus group B, Staphylococcus aureus, Salmonella species,
Escherichia coli and other coliforms, Capnocytophaga canimorsus,
and, rarely, Pseudomonas aeruginosa. Whether splenectomy
increases susceptibility to Neisseria meningitidis is unclear [4].
Babesiosis (transmitted by ticks in temperate and tropical
countries) is almost completely confined to asplenic patients,
and may be confused microscopically with Plasmodium falci-
parum infection [5]. Compared to normal individuals, asplenic
patients living in malaria-endemic areas are more commonly
parasitemic, and have delayed clearance of parasites after treat-
ment [6,7]; in addition, the disease may be severe or even fatal
[8]. Ehrlichiosis is more severe in asplenic individuals [9].
The risk of infection appears highest in the first 2 years post-
surgery [10]. In one series, 3.3% developed bacteremia during
the first month after surgery, but, notably, most of these patients
had gastrointestinal malignancies [11]. Thereafter, the risk of
sepsis is lower. Whereas some series indicate that the risk of
overwhelming post-splenectomy infection (OPSI) declines
with the time elapsed since splenectomy [1], other series do
not show a significant reduction [3]. Reasonable estimates of the
annual incidence of serious bacterial infections after splenect-
omy derived from cohort studies are 0.42 [12] and 0.23% per
year [11], with a lifetime risk of OPSI of 5% [1]. The risk is
higher in children, in those splenectomized for hematologic
conditions (especially malignancy), and in those who have
another cause for immunosuppression, such as corticosteroids
or cytotoxics. OPSI carries a mortality of 38–69% [3].
Although the risk of infection in the splenectomized has been
recognized for nearly 50 years [13], most splenectomized
patients have not received adequate advice or interventions
to reduce their risk of OPSI [3,11,14].
Theoretically, the risk of OPSI should be reduced by the
measures discussed below: but it should be recognized that no
trials of any of these interventions have been carried out.
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AUTOTRANSPL ANTATION AND SPLENIC
CONSERVATION
Embedding sections of splenic tissue in the greater omentum
can preserve a degree of splenic function. In one series, no
patients who underwent autotransplantation had episodes of
bacteremia, versus 4.8% of splenectomized patients who did not
[11].
However, other series do not show the same success. Splenic
repair may also be successfully used to conserve a damaged
spleen: in a study from Papua New Guinea, the prevalence of
malaria was 88% among patients who had a splenectomy for
trauma, versus 18% among those who had splenic conservation
and 16% of controls [6].
IMMUNIZ ATION
Pneumococcal vaccine
Because of the pre-eminent role of pneumococcal infection in
OPSI, all patients undergoing splenectomy should receive
immunization against S. pneumoniae using the 23-valent pneu-
mococcal polysaccharide vaccine (Pneumovax; Pnu-Immune),
which covers 73% of strains causing OPSI. If possible, vac-
cines should be given2 weeks prior to surgery, as the immune
response to the vaccines is thought to be better when the spleen
is intact. Although there are no data on the optimum timing of
vaccine given post-operatively, it is logical to give it at time of
discharge, thus minimizing the immunosuppressive effect of
surgery. Pneumococcal vaccine failures should be anticipated,
either because of strains not included in the vaccine, or because
of poor vaccine-induced antibody response as a consequence of
the splenectomy or underlying disease.
A booster dose is recommended at 3–5 years [14] or
5–10 years [15]. Pneumococcal vaccination may have other
protective effects. In a cohort of Danish patients, 60% of
whom were immunized against pneumococcus, the vaccination
was significantly protective against all bacteremia [11], possibly
because of cross-protective antibodies against Enterobacteria-
ciae [16].
A 7-valent pneumococcal protein conjugate vaccine has
recently become available (Prenevar). It is probably more
immunogenic, and does not require a booster dose. The value
of measuring antipneumococcal antibodies post-immunization
is unclear.
Hib vaccine
Although the role of H. influenzae type b in OPSI in the new
millennium is unclear, a single dose of H. influenzae type b
protein conjugate vaccine is thought to be immunogenic in
asplenic patients, and is recommended [15].
Meningococcal vaccine
Meningococcal vaccine is available in three forms, a mono-
valent protein–polysaccharide conjugate vaccine against C
strains, a polysaccharide vaccine against serogroups A and C,
or a quadrivalent vaccine containing A, C, Y and W135
polysaccharides. Although the role of meningococci in OPSI
is not clearly established, the increased severity of disease
suggests that the vaccine should be used. With the current
prevalence of serogroup C and the advantages of protein
conjugate vaccines, patients in Europe should receive this
vaccine. Travel to areas where other serogroups of meningo-
cocci are prevalent is an indication for revaccination with the
A, C, Y, W135 vaccine.
Influenza vaccine
Annual influenza vaccination is also recommended for asplenic
individuals [15]. All of the vaccines listed above can be given
together, if necessary.
PROPHYLACTIC ANTIBIOTICS
In children with sickle cell disease, prophylactic penicillin
conferred great protection against pneumococcal infections.
Similar studies have not been carried out in splenectomized
adults, and are unlikely ever to be conducted. Some guidelines
advise prophylactic antibiotics for the first 3–5 years after sple-
nectomy, but many data indicate that the risk of OPSI does not
decline with time. However, long-term antibiotic therapy may
be a risk factor for selection of resistant strains, and efficacy may
be reduced by non-compliance. Thus the decision of whether
to use prophylactic antibiotics or not depends largely on patient
and physician preference. Penicillin would provide prophylaxis
only against sensitive pneumococci, meningococci, and strep-
tococci, but is suitable for adults at 500 mg daily or twice daily.
Amoxicillin would be a preferred choice in children. Macro-
lides do not represent a suitable alternative of antibiotic resis-
tance—for example, currently 12% of pneumococci in UK
are resistant to macrolides. In penicillin-allergic individuals,
alternatives are either co-trimoxazole or a fluoroquinolone with
Gram-positive activity such as moxifloxacin.
STAND-BY ANTIBIOTICS
Whether asplenic patients receive daily prophylaxis or not, they
should be given a 5-day supply of stand-by antibiotics. Logical
choices for an adult would be co-amoxiclav 625 mg 8-hourly
or, for those with a history of a penicillin rash, cefuroxime
250 mg 12-hourly. For patients with serious penicillin allergy, a
fluoroquinolone with Gram-positive activity such as moxiflox-
acin could be used. Where there is a high prevalence of
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penicillin-resistant pneumococci (MIC> 1 mg/L), linezolid
600 mg 12-hourly would be suitable. Stand-by antibiotics will
need to be replaced if their shelf-life expires, and patients can
greatly extend the shelf-life by storing them in the household
refrigerator at 4 8C.
To ensure that they are used correctly, the antibiotics should
be accompanied by clear written instructions.
‘If you become suddenly unwell with a high temperature,
shivering or shaking, and feel dizzy or faint, you should
immediately take a dose of your stand-by antibiotic’.
‘Contact your own doctor at once’.
‘If your own doctor is not available or there is any delay, go at
once to the nearest hospital. Show this card and your antibiotics
to the hospital doctors’.
(Adapted from Spickett et al. [14])
TREATMENT OF OPSI
OPSI is a medical emergency requiring early recognition and
aggressive management. When patients present to general
practitioners, the latter should, if possible, take a blood culture,
immediately give parental penicillin, ceftriaxone, or similar
antibiotic, and transport the patient immediately to hospital.
In hospital, the patient should be resuscitated and managed in
the intensive therapy unit. A combination of antibiotics should
be given to cover the wide spectrum of bacteria implicated.
Where moderately or highly penicillin-resistant pneumococci
are prevalent, ceftriaxone plus vancomycin or teicoplanin (plus
rifampicin if highly resistant pneumococci are prevalent) pro-
vide suitable initial cover. A peripheral blood or buffy coat film
should be examined immediately for the presence of circulating
or intraleukocytic bacteria. If Gram-negative rods are seen,
cover for Pseudomonas should be added. The presence of
intracellular bacteria or morulae within leukocytes (suggestive
of ehrlichiosis), and intraerythrocytic parasites (malaria or
babesiosis) should be sought. Blood cultures are positive in
95% of cases of OPSI [1,3], and antibiotics can be modified
once the cultures are available. As well as intravenous antibiotics,
we advise intravenous immunoglobulin 0.4 g/kg daily for
3 days: although there are no studies to show it is beneficial,
there is good theoretical evidence for its use [17,18] and it is a
practice endorsed by others [19].
PATIENT INFORMATION AND AWARENESS
As well as written advice on immunizations and stand-by
antibiotics, patients should wear a medical bracelet (MedicAlert;
http://www.medicalert.co.uk) or carry a laminated medical
alert card [14]. This is intended to increase the awareness of
patients and their doctors, to increase compliance with pro-
phylactic and stand-by antibiotics, and to improve the speed and
appropriateness of treatment for OPSI. Patients should be
encouraged to obtain further information on splenectomy,
e.g. http://dspace.dial.pipex.com/lrf-/diseases/index.htm.
BITES AND WOUNDS
Patients should be aware of the danger of OPSI following
animal or human bites, or any other contaminated wound,
and should take prophylactic antibiotics—co-amoxiclav is an
ideal first choice.
MALARIA
When travelling to a malaria-endemic area, asplenic patients
should take particular care to avoid mosquito bites and should
take antimalarial prophylaxis with high efficacy. In this situa-
tion, doxycycline 100 mg daily would double as antibiotic and
antimalarial prophylaxis. Other antimalarial regimens with high
efficacy (but lacking antibiotic effect) are mefloquine 250 mg
weekly and atovaquone-proguanil one tablet daily. Asplenic
patients resident in malaria-endemic areas should consider
taking lifelong prophylaxis against malaria.
CONCLUSION
The simple interventions of immunization, prophylaxis and
stand-by antibiotics can be expected to reduce the frequency of
OPSI and its mortality. Unfortunately, splenectomy registers are
not commonly kept, and most asplenic patients do not receive
appropriate advice.
REFERENCES
1. Lynch AM, Kapila R. Overwhelming postsplenectomy infection.
Infect Dis Clin North Am 1996; 10(4): 693–707.
2. Gaston MH, Verter JI, Woods G et al. Prophylaxis with oral
penicillin in children with sickle cell anemia. A randomized trial.
N Engl J Med 1986; 314(25): 1593–9.
3. Waghorn DJ. Overwhelming infection in asplenic patients:
current best practice preventive measures are not being followed.
J Clin Pathol 2001; 54(3): 214–18.
4. Loggie BW, Hinchey EJ. Does splenectomy predispose to
meningococcal sepsis? An experimental study and clinical review.
J Pediatr Surg 1986; 21: 326–30.
5. Garnham PC, Donnelly J, Hoogstraal H, Kennedy CC, Walton
GA. Human babesiosis in Ireland: further observations and the
medical significance of this infection. BMJ 1969; 4(686): 768–70.
6. Boone KE, Watters DA. The incidence of malaria after
splenectomy in Papua New Guinea. BMJ 1995; 311(7015): 1273.
7. Looareesuwan S, Suntharasamai P, Webster HK, Ho M. Malaria in
splenectomized patients. report of four cases and review. Clin Infect
Dis 1993; 16(3): 361–6.
8. Bradley DJ, Warhurst DC, Blaze M, Smith V. Malaria imported
into the United Kingdom 1989 and 1990. CDR (Lond Engl Rev)
1991; 1(5): R45–8.
9. Rabinstein A, Tikhomirov V, Kaluta A, Gelfmann N, Iannini P,
Edwards L. Recurrent and prolonged fever in asplenic patients
 2001 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 7, 657–660
Davidson and Wall Infections in patients without a spleen 659
with human granulocytic ehrlichiosis. Q J Med 2000; 93(3):
198–201.
10. Holdsworth RJ, Irving AD, Cuschieri A. Postsplenectomy sepsis
and its mortality rate: actual versus perceived risks. Br J Surg 1991;
78: 1031–8.
11. Ejstrud P, Kristensen B, Hansen JB, Madsen KM, Schonheyder
HC, Sorensen HT. Risk and patterns of bacteraemia after
splenectomy: a population-based study. Scand J Infect Dis 2000;
32(5): 521–5.
12. Cullingford GL, Watkins DN, Watts AD, Mallon DF. Severe late
postsplenectomy infection. Br J Surg 1991; 78(6): 716–21.
13. King H, Schmacker HB. Splenic studies: I. Susceptibility to
infection after splenectomy performed in infancy. Ann Surg 1952;
136: 239–42.
14. Spickett GP, Bullimore J, Wallis J, Smith S, Saunders P. Northern
region asplenia register—analysis of first two years. J Clin Pathol
1999; 52(6): 424–9.
15. Salisbury DM, Begg NT, eds. Immunisation against infectious diseases.
London: HMSO, 1996.
16. Heidelberger M, Jann K, Jann B. Crossreactions of Escherichia coli
K and O polysaccharides in antipneumococcal and anti-Salmonella
sera. J Exp Med 1985; 162(4): 1350–8.
17. Offenbartl K, Christensen P, Gullstrand P, Prellner K.
Prophylactic effect of human immunoglobulin against pneumo-
coccal post-splenectomy sepsis in the rat. Infection 1986; 14(4):
167–9.
18. Camel JE, Kim KS, Tchejeyan GH, Mahour GH. Efficacy of
passive immunotherapy in experimental postsplenectomy sepsis
due to Haemophilus influenzae type b. J Pediatr Surg 1993; 28(11):
1441–4.
19. Bradley TM, Smoot EC 3rd, Graham DR, Kucan JO, Hussmann
J. Overwhelming postsplenectomy sepsis in a patient with burns: a
case report and a rational approach to treatment. J Burn Care
Rehabil 1995; 16(5): 525–30.
 2001 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 7, 657–660
660 Clinical Microbiology and Infection, Volume 7 Number 12, December 2001
